Expert Analysis- Healthcare Value Assessment Frameworks Have Advanced, But Wholesale Adoption Still Not Wise

Published Sep 23, 2019

Lawrenceville, NJ, USA—September 23, 2019—Value in Health, the official journal of ISPOR—the professional society for health economics and outcomes research, announced today the publication of an analysis showing that while value assessment frameworks are moving closer to meeting the challenge of accurately measuring value and reliably informing healthcare decisions, more progress is needed before widespread adoption and use. The study, “As Value Assessment Frameworks Evolve, Are They Finally Ready for Primetime?,” was published in the September 2019 issue of Value in Health. An accompanying commentary by Peter J. Neumann, ScD, Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, Boston, MA, USA, appears in the same issue of Value in Health.

Authors Dubois and Westrich briefly describe the evolution of the value assessment framework landscape in the United States, including new entrants and updated frameworks. To assess whether this evolution successfully advances the field of value assessment, they examined the current frameworks actively conducting assessments—those from the Institute for Clinical and Economic Review, Innovation and Value Initiative, and National Comprehensive Cancer Network—relative to 6 key considerations for improvement. These 6 considerations were identified via a prior peer-reviewed analysis based on the National Pharmaceutical Council’s Guiding Practices for Patient-Centered Value Assessment. They include:

  1. Value assessments should be transparent and reproducible
  2. Value is dynamic and needs to be considered and captured as such
  3. Value assessments should adopt broad system perspectives in what they assess and how they assess it
  4. Value assessments should incorporate what is important to patients, even if the end user for a framework is the payer
  5. A diversity of value assessment approaches that reflect the differing needs of stakeholders should remain; value assessments should reflect user preferences
  6. Assessments of value should be separate from assessments of budget impact and affordability

The analysis found that value assessment frameworks are moving closer to meeting the challenge of accurately measuring value and reliably informing healthcare decisions, but more progress is needed before widespread adoption and use.

“Our investigation shows that the field of value assessment has advanced in most areas,” said author Kimberly Westrich, MA, Vice President of Health Services Research, The National Pharmaceutical Council, Washington, DC, USA. “Indeed, each of the 6 considerations has been addressed in some way by at least one framework. However, more progress is needed before the widespread adoption of frameworks for decision making. Users must be aware that these assessments have limitations, and wholesale adoption is not wise. While value assessments are potential inputs that can be considered for healthcare decision making, none of them should be the sole input for these decisions. Considering the limitations, they should, at most, be only one of many tools in the toolbox.”

###

ABOUT ISPOR
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Web: www.ispor.org | LinkedIn: www.linkedin.com/company/ispororg | Twitter: www.twitter.com/ispororg (@ISPORorg) | YouTube: www.youtube.com/ispororg | Facebook: www.facebook.com/ispororg | Instagram: www.instagram.com/ispororg

ABOUT VALUE IN HEALTH
Value in Health (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions. The journal’s 2018 impact factor score is 5.037. Value in Health is ranked 4th among 81 journals in health policy and services, 5th among 98 journals in healthcare sciences and services, and 11th among 363 journals in economics. Value in Health is a monthly publication that circulates to more than 10,000 readers around the world.
Web: www.ispor.org/valueinhealth | Twitter: www.twitter.com/isporjournals (@ISPORjournals)

Related Stories

ISPOR Global Panel Proposes New Structure to Improve Definitions of Digital Health Interventions

Apr 9, 2024

ISPOR—The Professional Society for Health Economics and Outcomes Research announced today the publication of a report from the ISPOR Digital Health Special Interest Group that proposes a new framework to help standardize and clarify definitions used for digital health interventions. The report, “The PICOTS-ComTeC Framework for Defining Digital Health Interventions: An ISPOR Special Interest Group Report” was published in the April 2024 issue of Value in Health.

ISPOR International Panel Calls for Consensus on Medication Adherence Measures

Feb 26, 2024

ISPOR—The Professional Society for Health Economics and Outcomes Research announced the publication of a new report from the ISPOR Medication Adherence and Persistence Special Interest Group revealing significant inconsistencies in how researchers measure the effectiveness of interventions aimed at improving medication adherence. The report, “A Systematic Review of Outcomes for Assessment of Medication Adherence Enhancing Interventions: An ISPOR Special Interest Group Report” was published in the February 2024 issue of Value in Health.

Global Experts Highlight Concerns With Implementation of IRA-Mandated Medicare Drug Price Negotiation Program

Dec 5, 2023

Value in Health announced the publication of 2 new commentaries by leading experts in health economics and outcomes research, both of which raise important questions as the Centers for Medicare & Medicaid Services move forward to implement the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×